IP Library Granted Patent US 10,408,784
Granted Patent B2
US 10,408,784 · App. 15/584,660 · Granted Sep 10, 2019

Determining blood glucose in a small volume sample receiving cavity and in a short time period

Inventor: Christopher D. Wilsey (Carmel, IN)
Assignees: Roche Diabetes Care, Inc.; Roche Operations Ltd.
G01N27/3275C12Q1/006G01N27/3272
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,408,784
App. No.
15/584,660
Granted
Sep 10, 2019
Kind
B2
Abstract

The concentration of glucose in a blood sample is determined by methods utilizing test strips having a sample receiving cavity having a volume from about 0.3 μl to less than 1 μl and determining the glucose concentration within a time period from about 3.5 seconds to about 8 seconds.

Claims (17)

1. A method of analyzing an analyte in a biological fluid sample, the method comprising:

providing an electrochemical sensor comprising:

a flexible substrate;

a conductive pattern disposed on the flexible substrate, the conductive pattern comprising:

an interdigitated array comprising first and second, electrodes electrically isolated from each other, the first electrode comprising first electrode elements electrically connected to a first common element, the second electrode comprising second electrode elements electrically connected to a second common element the number of first electrode elements being one more or one less than the number of second electrode elements;

first and second pads and first and second connectors electrically connecting the first and second pads to the first and second electrodes, respectively;

wherein each electrode element comprises a width of about 50 micrometers, and wherein the electrode elements of the first electrode are spaced substantially equally from the electrode elements of the second electrode by gaps, each gap having, a distance of about 25 micrometers;

a chemical coating disposed over at least a portion of the first electrode, the chemical coating configured for reacting with an analyte to produce an electroactive reaction product; and

a capillary chamber overlying at least a portion of the interdigitated array and configured to direct flow of a biological fluid sample into contact with the chemical coating on the first electrode, the capillary chamber having a volume from about 250 nanoliters to about 400 nanoliters;

contacting the capillary chamber with a biological fluid sample, the capillary chamber directing the biological fluid sample into contact with the first and second electrodes and the chemical coating to at least partly solubilize or hydrate the chemical coating;

detecting the contacting of the first and second electrodes by the biological fluid sample and starting a delay period of about 2 seconds allowing the analyte and chemical coating to react and to produce electroactive reaction product;

after the delay period, starting an assay period by applying an assay potential across the first and second electrodes for inducing an assay current across the electrodes resulting from oxidation of the electroactive reaction product at one of the first and second electrodes, the assay current reaching a steady-state current;

measuring a magnitude of the assay current during the assay period after the assay current has reached the steady-state current, the measuring step being performed beginning about 2.1 seconds after the start of the delay period; and

correlating the magnitude of the assay current to a concentration of the analyte in the biological fluid sample.

2. The method of claim 1 , wherein the biological fluid sample comprises whole blood, and the analyte comprises glucose.

3. The method of claim 1 , wherein the measuring step is performed at a fixed assay period point during the assay period, and wherein the magnitude of the assay current at the fixed assay period point correlates generally linearly with the concentration, of the analyte over a range of concentrations.

4. The method of claim 3 , wherein the biological fluid sample comprises whole blood, the analyte comprises glucose, and the concentration range comprises from about 0 to about 600 mg/dL.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2024
From: ROCHE OPERATIONS LTD.
To: ROCHE DIABETES CARE, INC.
Reel/Frame 067204/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2017
From: WILSEY, CHRISTOPHER D
To: ROCHE DIAGNOSTICS CORPORATION
Reel/Frame 042921/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2017
From: ROCHE DIAGNOSTICS CORPORATION
To: ROCHE DIAGNOSTICS OPERATIONS, INC
Reel/Frame 042921/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2017
From: ROCHE DIAGNOSTICS OPERATIONS, INC
To: CORANGE INTERNATIONAL LIMITED
Reel/Frame 042922/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2017
From: CORANGE INTERNATIONAL LIMITED
To: ROCHE OPERATIONS LTD.
Reel/Frame 042922/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2017
From: ROCHE DIAGNOSTICS OPERATIONS, INC
To: ROCHE DIABETES CARE, INC.
Reel/Frame 043098/0236 →
Continuity (11)
Continuation 14695528 · Apr 24, 2015
Continuation 13929293 · Jun 27, 2013
Continuation 13719967 · Dec 19, 2012
Continuation 13433779 · Mar 29, 2012
Continuation 13339598 · Dec 29, 2011
Continuation 12477239 · Jun 3, 2009
Continuation 11677737 · Feb 22, 2007
Continuation 10382322 · Mar 5, 2003
Continuation In Part 10264785 · Oct 4, 2002
Continuation In Part 10264891 · Oct 4, 2002
Related Publication 20170328858A1 · Nov 16, 2017